免疫肿瘤药物市场：依治疗类型、疾病类型、通路、地区分类

预计2024年全球免疫肿瘤药物市场规模为272.5亿美元，预计2031年将达891亿美元，2024年至2031年复合年增长率为18.4%。

图：2024 年按地区分類的免疫肿瘤药物市场占有率（%）

免疫肿瘤药物利用人体的免疫系统来对抗癌症，并已被证明可以提高多种癌症类型的存活率。这些药物增强针对癌细胞的免疫反应，并提高存活率。主要核准的免疫肿瘤药物类别包括查核点抑制剂、癌症疫苗和特异性免疫疗法。不断临床研究和开发具有更高功效和安全性的新药正在推动市场成长。

市场动态：

全球免疫肿瘤药物市场的成长主要是由全球癌症发生率上升所推动的。由于生活型态的改变、预期寿命的延长、污染等环境因素，癌症发生率逐年上升。与传统癌症治疗相比，免疫肿瘤药物已证明具有长期疗效和存活率。这正在促进药物研发并增加药物核准。伴同性诊断的发展将透过识别最适合免疫治疗的患者群体来推动市场成长。然而，这些药物的高成本可能会限制其在价格敏感地区的采用。此外，免疫相关副作用等安全问题也可能阻碍市场成长。正在进行的评估新适应症、药物组合和个人化疗法的临床试验可能会在不久的将来为市场成长提供利润丰厚的机会。

本研究的主要特点

• 该报告对全球免疫肿瘤药物市场进行了详细分析，并提供了以2023年为基准年的预测期（2024-2031年）的市场规模（十亿美元）和年复合成长率（CAGR%）。正在做。
• 它还揭示了各个细分市场的潜在商机，并说明了该市场有吸引力的投资提案矩阵。
• 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
• 它根据公司亮点、产品系列、主要亮点、财务表现和策略等参数，介绍了全球免疫肿瘤药物市场的主要企业。
• 该报告的见解将使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
• 全球免疫肿瘤药物市场报告针对该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
• 透过用于分析全球免疫肿瘤药物市场的各种策略矩阵，将有助于相关人员做出决策。

目录

第一章 研究目的与前提

• 研究目的
• 先决条件
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章 市场动态、法规与趋势分析

• 市场动态
  • 促进因素
  • 抑制因素
  • 机会
• 影响分析
• 市场趋势
• 主要进展
• 监管场景
• 收购和合作场景
• 资金筹措和投资
• PEST分析
• 波特的分析

第四章全球免疫肿瘤药物市场 - 冠状病毒（COVID-19）大流行的影响

• 整体影响
• 政府倡议
• COVID-19 对市场的影响

第五章全球免疫肿瘤药物市场，依治疗类型，2019-2031

• 免疫查核点抑制剂
• PD-1
• PD-LI
• CTLA-4
• 免疫系统调节剂
• 癌症疫苗
• 溶瘤病毒
• 其他的

第六章全球免疫肿瘤药物市场，依疾病类型，2019-2031

• 恶性黑色素瘤
• 肺癌
• 血癌
• 肾臟细胞癌
• 摄护腺癌
• 膀胱癌
• 其他的

第7章全球免疫肿瘤药物市场，依通路，2019-2031

• 医院药房
• 零售药房
• 网路药房

第八章全球免疫肿瘤药物市场，按地区，2019-2031

• 拉丁美洲
• 欧洲
• 亚太地区
• 中东

第9章 竞争格局

• 公司简介
  • Coloplast Corp
  • Bristol Myers Squibb Company
  • Novartis AG
  • F. Hoffmann-LA Roche Ltd.
  • Merck &Co., Inc.
  • GSK Plc.
  • Eli Lilly and Company
  • Fresenius Kabi AG
  • Pfizer Inc.
  • AbbVie Inc.
  • Genentech Inc.
  • Sanofi
  • AstraZeneca
  • Bayer AG
  • Bluebird Bio, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Amgen Inc.

第10章分析师建议

• 命运之轮
• 分析师观点
• 一致的机会图

第十一章 参考文献与调查方法

• 参考
• 调查方法

Global immuno-oncology drugs market is estimated to be valued at USD 27.25 Bn in 2024 and is expected to reach USD 89.10 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 18.4% from 2024 to 2031.

Figure. Immuno-oncology Drugs Market Share (%), By Region 2024

Immuno-oncology drugs use the body's immune system to fight cancer, and have demonstrated improved survival rates for various cancer types. These drugs boost the immune response against cancer cells, and thus, improve survival outcomes. Some major immuno-oncology drug classes approved include checkpoint inhibitors, cancer vaccines, and nonspecific immunotherapies. Continued clinical research and development of novel agents with improved efficacy and safety profiles can drive the market growth.

Market Dynamics:

Global immuno-oncology drugs market growth is primarily driven by rising cases of cancer worldwide. Cancer incidence has been rising year-on-year owing to lifestyle changes, increased life expectancy, and environmental factors like pollution. Immuno-oncology drugs have demonstrated long-term efficacy and survival benefits as compared to conventional cancer therapies. This boosts pharmaceutical R&D and increases drug approvals. The developments in companion diagnostics identify patient populations most suitable for immunotherapies, thus, driving the market growth. However, high costs of these drugs can restrict its adoption in price-sensitive regions. Safety issues like immune-related adverse effects can also hamper the market growth. Ongoing clinical trials evaluating new indications, drug combinations, and personalized therapies can offer lucrative opportunities for the market growth in the near future.

Key Features of the Study:

• This report provides in-depth analysis of the global immuno-oncology drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global immuno-oncology drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Bristol-Myers Squibb, Merck, Roche, Pfizer, AstraZeneca, and Novartis
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global immuno-oncology drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global immuno-oncology drugs market

Detailed Segmentation-

• By Treatment Type
  • Immune Checkpoint Inhibitors
  • PD-1
  • PD-LI
  • CTLA-4
  • Immune System Modulators
  • Cancer Vaccines
  • Oncolytic Virus
  • Others
• By Disease Type
  • Melanoma
  • Lung Cancer
  • Blood Cancer
  • Renal Cell Carcinoma
  • Prostate Cancer
  • Bladder Cancer
  • Others (Breast Cancer, Thyroid Cancer, etc.)
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Coloplast Corp
  • Bristol Myers Squibb Company
  • Novartis AG
  • F. Hoffmann-LA Roche Ltd.
  • Merck & Co., Inc.
  • GSK Plc.
  • Eli Lilly and Company
  • Fresenius Kabi AG
  • Pfizer Inc.
  • AbbVie Inc.
  • Genentech Inc.
  • Sanofi
  • AstraZeneca
  • Bayer AG
  • Bluebird Bio, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Amgen Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Treatment Type
  • Market Snapshot, By Disease Type
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Immuno-oncology Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Immuno-oncology Drugs Market, By Treatment Type, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Immune Checkpoint Inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• PD-1
• PD-LI
• CTLA-4
• Immune System Modulators
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Cancer Vaccines
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Oncolytic Virus
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Immuno-oncology Drugs Market, By Disease Type, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Melanoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Lung Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Blood Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Renal Cell Carcinoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Prostate Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Bladder Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Immuno-oncology Drugs Market, By Distribution Channel, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Immuno-oncology Drugs Market, By Region, 2019 - 2031, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2031
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2019 - 2031, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • Coloplast Corp
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Bristol Myers Squibb Company
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • F. Hoffmann-LA Roche Ltd.
  • Merck & Co., Inc.
  • GSK Plc.
  • Eli Lilly and Company
  • Fresenius Kabi AG
  • Pfizer Inc.
  • AbbVie Inc.
  • Genentech Inc.
  • Sanofi
  • AstraZeneca
  • Bayer AG
  • Bluebird Bio, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Amgen Inc.

10. Analyst Recommendation

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About Us and Sales Contact